Vasodilatory Shock Clinical Trial
Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial to Evaluate the Efficacy and Safety of Angiotensin II Injection in the Background Treatment of Catecholamines and Other Vasopressors in Chinese Adult Patients With Refractory Distributive Shock
A randomized, double-blind, placebo-controlled study on the treatment of refractory distributed shock with angiotensin II injection, with a random ratio of 1:1. Assuming a success rate of 25% for the main therapeutic endpoint in the control group and 50% for the experimental group, a total of 214 subjects will be enrolled, including 107 in the experimental group and 107 in the control group.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03378466 -
Heparin Anticoagulation in Septic Shock
|
Phase 2 | |
| Recruiting |
NCT05824767 -
Serum Biomarkers to Predict Response to Angiotensin II in Septic Shock
|
Phase 4 | |
| Approved for marketing |
NCT03245528 -
Expanded Access for LJPC-501
|
N/A |